Email this article 
EXPERIENCE WITH OCTREOTIDE IN PATIENTS WITH CASTRATION REFRACTORY PROSTATE CANCER
- Authors: Ganov D.I.1,2, Varlamov S.A.1,2
-
Affiliations:
- Altai State Medical University
- Altai Branch, N.N. Blokhin Russian Cancer Research Center, Кussian Academy of Medical Sciences, Barnaul
- Issue: Vol 7, No 4 (2011)
- Pages: 71-73
- Section: PROSTATE CANCER
- Published: 30.12.2011
- URL: https://oncourology.abvpress.ru/oncur/article/view/224
- DOI: https://doi.org/10.17650/1726-9776-2011-7-4-71-73
- ID: 224
Cite item
Full Text
Abstract
Fifteen patients with castration refractory prostate cancer have been treated with sustained-release octreotide in combination with dexamethasone at the Altai Territory Oncology Dispensary since 2008. Control PSA test revealed that 9 (60 %) patients had positive changes; tumor process stabilization was noted in 4 (26.7 %) and only 2 (13.3 %) were found to have disease progression. Thus, more than 86 % of patients responded to combination treatment with sustained-release octreotide + dexamethasone. Octreotide treatment caused no serious specific adverse toxic reactions.
About the authors
D. I. Ganov
Altai State Medical University; Altai Branch, N.N. Blokhin Russian Cancer Research Center, Кussian Academy of Medical Sciences, Barnaul
Author for correspondence.
Email: ganov2@rambler.ru
Russian Federation
S. A. Varlamov
Altai State Medical University; Altai Branch, N.N. Blokhin Russian Cancer Research Center, Кussian Academy of Medical Sciences, Barnaul
Email: ganov2@rambler.ru
Russian Federation
References
Supplementary files
